Login / Signup

Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening.

Jörg Schmidtke
Published in: Genes (2022)
Hereditary hemochromatosis (HH) is a rather frequent, preventable disease because the progressive iron overload affecting many organs can be effectively reduced by phlebotomy. Even before the discovery of the major gene, HFE , in 1996, hemochromatosis was seen as a candidate for population-wide screening programmes. A US Centers of Disease Control and the National Human Genome Research Institute expert panel convened in 1997 to consider genotype-based HH population-wide screening and decided that the scientific evidence available at that time was insufficient and advised against. In spite of a large number of studies performed within the last 25 years, addressing all aspects of HH natural history, health economics, and social acceptability, no professional body worldwide has reverted this decision, and HH remains a life-threatening condition that often goes undetected at a curable stage.
Keyphrases
  • healthcare
  • multiple sclerosis
  • public health
  • genome wide
  • gene expression
  • risk assessment
  • quality improvement
  • dna methylation
  • clinical practice
  • health information
  • climate change
  • adverse drug